Cardiovascular Issues in Patients with Malignant Lymphoma: A Narrative Review

Article Sidebar

PDF Download
Published Feb 28, 2023
DOI: https://doi.org/10.18103/mra.v11i2.3636

Downloads

Download data is not yet available.

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Author Registration

Join the Society

The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.

Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.

Membership

Main Article Content

Motoharu Shibusawa, MD
IMS group Shinmatsudo Central General Hospital, Department of Hematology, Chiba, Japan
Erika Imamine, MD
IMS group IMS Tokyo Katsushika General Hospital, Department of Cardiology, Tokyo, Japan

Abstract

Cardiovascular issues are important concerns in malignant lymphoma treatment. These issues can be broadly categorized into two groups: the invasion of malignant lymphoma into the heart and cardiovascular disease related to malignant lymphoma treatment. In terms of malignant lymphoma invasion of the heart, the presence of a heart lesion of malignant lymphoma often presents with heart-related symptoms and findings such as chest pain, heart failure, and arrhythmias. Notably, heart failure and arrhythmias can be fatal. The identification of heart lesions of malignant lymphoma will result in appropriate management and survival improvement. As for cardiovascular disease associated with malignant lymphoma treatment, the incidence and types of cardiovascular disease, management, and follow-up planning should be identified before starting treatment. This identification and plan will allow an understanding of the risk of developing cardiovascular disease and appropriate management and follow-up. In clinical practice, it is important to keep in mind that cardiac issues in patients with malignant lymphoma should be identified, assessed, and managed before initiating treatment.


 

Article Details

How to Cite
SHIBUSAWA, Motoharu; IMAMINE, Erika. Cardiovascular Issues in Patients with Malignant Lymphoma: A Narrative Review. Medical Research Archives, [S.l.], v. 11, n. 2, feb. 2023. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/3636>. Date accessed: 30 dec. 2024. doi: https://doi.org/10.18103/mra.v11i2.3636.
ABNT APA BibTeX CBE EndNote - EndNote format (Macintosh & Windows) MLA ProCite - RIS format (Macintosh & Windows) RefWorks Reference Manager - RIS format (Windows only) Turabian
Issue
Vol 11 No 2 (2023): February Issue, Vol.11 Issue 2
Section
Review Articles

The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.

 

References

1. Press OW, Lichtman MA. General considerations for lymphomas: epidemiology, etiology, heterogeneity, and primary EXTRANODAL DISEASE. In: Kenneth K, Marshall A L, Josef P, et al., eds. Williams Hematology. 9th ed. McGraw-Hill Education; 2016.
2. Carras S, Berger F, Chalabreysse L, et al. Primary cardiac lymphoma: diagnosis, treatment and outcome in a modern series. Hematol Oncol. 2017;35(4):510-519.
3. Petrich A, Cho SI, Billett H. Primary cardiac lymphoma: an analysis of presentation, treatment, and outcome patterns. Cancer. 2011;117(3):581-589.
4. Asadian S, Rezaeian N, Hosseini L, Toloueitabar Y, Hemmati Komasi MM. The role of cardiac CT and MRI in the diagnosis and management of primary cardiac lymphoma: A comprehensive review. Trends Cardiovasc Med. 2021.
5. Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. European Journal of Heart Failure. 2020;22(11):1945-1960.
6. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Heart Journal. 2016;37(36):2768-2801.
7. Lam KY, Dickens P, Chan AC. Tumors of the heart. A 20-year experience with a review of 12,485 consecutive autopsies. Arch Pathol Lab Med. 1993;117(10):1027-1031.
8. Lamba G, Frishman WH. Cardiac and pericardial tumors. Cardiol Rev. 2012;20(5):237-252.
9. Tai CJ, Wang WS, Chung MT, et al. Complete atrio-ventricular block as a major clinical presentation of the primary cardiac lymphoma: a case report. Jpn J Clin Oncol. 2001;31(5):217-220.
10. Boddicker NJ, Larson MC, Castellino A, et al. Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era. American Journal of Hematology. 2021;96(8):979-988.
11. Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2018;104(12):971-977.
12. Sawicki KT, Sala V, Prever L, Hirsch E, Ardehali H, Ghigo A. Preventing and Treating Anthracycline Cardiotoxicity: New Insights. Annu Rev Pharmacol Toxicol. 2021;61:309-332.
13. Maraldo MV, Levis M, Andreis A, et al. An integrated approach to cardioprotection in lymphomas. The Lancet Haematology. 2022;9(6):e445-e454.
14. Hequet O, Le QH, Moullet I, et al. Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in Adults. Journal of Clinical Oncology. 2004;22(10):1864-1871.
15. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213-220.
16. Burger JA. Bruton Tyrosine Kinase Inhibitors: Present and Future. Cancer J. 2019;25(6):386-393.
17. Brown JR, Moslehi J, O’Brien S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102(10):1796-1805.
18. Guha A, Derbala MH, Zhao Q, et al. Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies. J Am Coll Cardiol. 2018;72(6):697-698.
19. Waliany S, Lee D, Witteles RM, et al. Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure. Annual Review of Pharmacology and Toxicology. 2021;61(1):113-134.
20. Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nature Reviews Clinical Oncology. 2019;16(9):563-580.
21. Moslehi JJ, Salem J-E, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. The Lancet . 2018;391(10124):933.
22. Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018;71(16):1755-1764.
23. Tocchetti CG, Ameri P, de Boer RA, et al. Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. Cardiovasc Res. 2020;116(11):1820-1834.
24. Guha A, Addison D, Jain P, et al. Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System Analysis. Biology of Blood and Marrow Transplantation. 2020;26(12):2211-2216.
25. de Vries S, Schaapveld M, Janus CPM, et al. Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients. J Natl Cancer Inst. 2021;113(6):760-769.